OPEN ACCESS

Middle East Research Journal of Medical Sciences
ISSN: 2789-7699 (Print) & ISSN: 2958-2024 (Online)
Frequency: Bi-Monthly
DOI: https://doi.org/10.36348/merjms.2024.v04i06.007

KUWAIT SCHOLARS PUBLISHER
Website: http://www.kspublisher.com/
Email: office@kspublisher.com

Etiology, Diagnosis, and Clinical Management of Vulvodynia (Vulvar Pain)

Ramazan Bayirli[1*]
[1]Department of Gynecology, Eskişehir Gurlife Hospital, Eskisehir, Turkey

Abstract: Vulvodynia is a chronic condition characterized by pain and discomfort in the vulvar vestibule, the area surrounding the vaginal opening. The etiology and pathophysiology of vulvodynia are complex and multifactorial. Current evidence points to a combination of peripheral inflammation, neural sensitization, hormonal dysregulation, and psychosocial factors. It typically manifests as sharp, burning pain or discomfort localized to the vestibule. An individualized, multimodal approach is vital in the treatment of vulvodynia. Conservative therapy is often the first line of treatment, with pharmacological and surgical options considered when these are insufficient. Emerging therapeutic approaches include platelet-rich plasma and low-level laser therapies. The heterogeneity of vulvodynia and the lack of a standardized diagnostic approach present significant challenges in clinical practice and research. Future studies should focus on elucidating the underlying pathophysiology of vulvodynia, emphasizing identifying biomarkers that may facilitate early diagnosis and targeted treatments. Advances in understanding the roles of central sensitization, neuroinflammation, and genetic predispositions may pave the way for more personalized and effective treatments. Vulvodynia significantly affects women's physical, emotional, and sexual health. Although progress has been made in understanding the potential underlying mechanisms, many gaps remain in its effective management. A multidisciplinary approach that includes medical, physical, and psychological therapies offers the best outcomes for patients. However, further research is necessary to develop more effective, individualized treatments and to improve the overall quality of care for women suffering from this condition.

Keywords: Vulvadynia, Vulva, Vestibule, Etiology, Pathophysiology, Dyspareunia.

Review Paper

***Corresponding Author:**
Ramazan Bayirli
Department of Gynecology, Eskişehir Gurlife Hospital, Eskisehir, Turkey

How to cite this paper:
Ramazan Bayirli (2024). Etiology, Diagnosis, and Clinical Management of Vulvodynia (Vulvar Pain). *Middle East Res J. Med. Sci, 4*(6): 199-206.

Article History:
| Submit: 16.10.2024 |
| Accepted: 15.11.2024 |
| Published: 29.11.2024 |

INTRODUCTION

Vulvodynia is a chronic condition characterized by pain and discomfort in the vulvar vestibule, the area surrounding the vaginal opening [1]. This condition primarily manifests as sensations of burning, stinging, or irritation, often exacerbated by pressure, friction, or sexual activity, leading to significant impairment in quality of life [2]. The etiology of vulvodynia is multifactorial and not yet fully understood; potential contributing factors include genetic predispositions, hormonal imbalances, inflammatory responses, and nerve fiber proliferation [3].

Clinically, patients with vulvodynia typically present with localized tenderness in the Skene and Bartholin glands [4], and diagnostic assessment often reveals allodynia or hyperalgesia, where typically non-painful stimuli elicit pain [5]. Histopathological studies have shown increased nerve density and immune activation in vestibular tissue; however, the underlying mechanisms remain unclear [6].

Managing vulvodynia is challenging and generally requires a multimodal approach, encompassing physical therapy, pharmacological interventions (such as topical anesthetics, tricyclic antidepressants, or anticonvulsants), and psychological support [7]. In certain resistant cases, surgical intervention, such as vestibulectomy, may be considered [8]. Emerging research explores novel therapeutic strategies, including neuromodulation and targeted immunotherapies, aimed at addressing the underlying pathophysiology of this complex condition [9].

This syndrome underscores the need for ongoing research into the interplay among neural, immune, and hormonal factors to understand better and alleviate the burden of vulvodynia [10]. This review aims to discuss the significance of multidisciplinary management strategies that integrate medical, psychological, and sexual health support for patients alongside continued exploration of vulvodynia's underlying causes.

ETIOLOGY

Although the etiology of vulvodynia has not yet been fully elucidated, several potential contributing factors have been identified [11]. One of the most widely accepted theories suggests that an initial event, such as infection, trauma, or hormonal change, triggers an inflammatory response, which subsequently leads to chronic pain [12]. Studies indicate that women with vulvodynia often report a history of recurrent vulvovaginal infections (13), with specific evidence suggesting that Candida species may sensitize nociceptors in the vulvar region, resulting in hyperalgesia and allodynia [14].

Another possible contributing factor is hormonal dysregulation [15]. Several studies suggest that low estrogen levels, particularly among women using oral contraceptives, may contribute to the condition. Reduced estrogen levels can lead to atrophy and thinning of the vulvar epithelium, rendering it more vulnerable to mechanical irritation and inflammation. Furthermore, some evidence suggests that androgen deficiency might play a role in pathogenesis, as decreased androgen levels may impair the function of vestibular glands, contributing to vestibular tissue dysfunction [16].

Genetic predisposition may also be a risk factor [17]. Certain studies have identified an association between vulvodynia and specific genetic polymorphisms, particularly those involved in inflammatory and pain pathways, suggesting a potential genetic susceptibility that could exacerbate an individual's response to local irritants or infections [17, 18].

PATHOPHYSIOLOGY

The pathophysiology of vulvodynia involves a complex interplay between peripheral and central mechanisms of pain perception [19]. On the peripheral level, chronic inflammation in the vestibular region is believed to alter nerve function, especially in C-fibers that transmit pain signals to the brain, leading to sensitization [17]. This peripheral sensitization may explain why even mild physical stimuli, such as light pressure, provoke disproportionate pain responses in women with vulvodynia [17].

Histopathological examinations of vestibular tissue in affected individuals often reveal increased immune cell infiltration, particularly of mast cells, and elevated concentrations of pro-inflammatory cytokines. These findings support that an abnormal immune response may contribute to persistent inflammation and pain in the vestibule [20].

At the central level, increasing evidence suggests that women with vulvodynia may experience central sensitization, whereby the central nervous system becomes overly reactive to pain stimuli [19, 21]. This process may amplify pain signals originating from the periphery, contributing to the chronic nature of the condition. Functional brain imaging studies have shown altered pain processing in brain regions associated with pain perception, such as the anterior cingulate cortex and insula, in women with vulvodynia [22].

Psychosocial factors, such as anxiety, depression, and sexual dysfunction, are also believed to modulate pain perception in vulvodynia. Chronic pain conditions are often associated with adverse psychological effects, and vulvodynia is no exception. A biopsychosocial model, which posits that psychological and social stressors contribute to pain persistence, has been suggested as a comprehensive framework for understanding vulvodynia [23].

The etiology and pathophysiology of vulvodynia are complex and multifaceted. Current evidence indicates that a combination of peripheral inflammation, neural sensitization, hormonal dysregulation, and psychosocial factors plays a significant role in the condition [7, 24]. Although substantial progress has been made in understanding vulvodynia, further research is needed to elucidate the precise molecular mechanisms involved and to develop more effective, targeted therapies. A comprehensive treatment approach that addresses both the biological and psychological aspects of vulvodynia will provide the best outcomes for affected women.

Clinical Presentation and Diagnosis

Vulvodynia is typically characterized by sharp, burning pain or discomfort in the vestibule, often triggered by physical contact such as sexual intercourse, tampon use, or tight clothing. Pain is usually localized but may radiate to surrounding areas. Diagnosis of vulvodynia is primarily clinical, relying on patient history and physical examination, including the cotton swab test. In this test, mild pressure applied to the vestibule reproduces the pain. Prior to confirming the diagnosis, it is essential to rule out other potential causes of vulvar pain, such as infections, dermatological conditions, and neuropathies.

A comprehensive clinical evaluation is required to diagnose vulvodynia, focusing on excluding other potential causes of vulvar pain, such as infections, dermatological conditions, or neoplasms. The cotton-swab test is employed to localize the pain to the vestibular area by applying gentle pressure to specific vestibule regions to elicit characteristic discomfort. Additionally, a pelvic examination is necessary to rule out pelvic floor dysfunction or muscle spasms, which are commonly associated with this condition. Due to the substantial emotional burden it imposes, a psychological evaluation is also warranted.

In the diagnostic approach to vulvodynia, the psychosexual history should be examined, focusing on

any preexisting sexual dysfunction. Current sexual practices and other lifetime sexual difficulties, including issues with desire, arousal, orgasm, and satisfaction, should be assessed alongside dyspareunia. General avoidance behaviors, such as avoiding genital contact, and a lifetime history of dyspareunia may indicate concurrent primary vaginismus.

A detailed medical history, including diet and medication use, is essential. Any food intolerances, allergies, hormonal treatments, and all past systemic and genital treatments should be reviewed and documented. Previous vaginal infections and sexually transmitted diseases, including Candida, Gardnerella, Human Papillomavirus, and Herpes, should be investigated, with testing conducted if an ongoing infection is suspected. The characteristics and duration of symptoms should be evaluated, along with a thorough physical examination. Vaginal pH should be objectively tested with a vaginal swab for 10-15 seconds during the gynecological examination.

The nature of the pain should be explored by questioning its location, timing, and associated complaints to identify the biological etiology related to dyspareunia reliably. A precise pain map outlining painful points within the external genitalia, middle, and deep vagina, should be created. During the examination, the physician should also note confounding factors such as defensive levator ani muscle contraction, which can contribute to levator ani myalgia over time and exacerbate pain perception and penetration difficulties. Such factors necessitate a more extensive therapeutic approach aimed at relaxing a tightened pelvic floor.

Finally, the nature and quality of sexual intercourse should be evaluated, focusing on the couple's emotional, sexual, and interpersonal functioning. Since certain aspects of a partner's functionality can affect a woman's sexual functionality, any sexual or genital symptoms in the partner should also be recorded.

Treatment Approaches

Treatment of vulvodynia remains a complex and evolving field. Given its multifactorial nature, an individualized, multimodal approach is essential for achieving optimal outcomes. While conservative and pharmacological therapies offer relief for many women, more invasive treatments, including surgery, may be necessary for refractory cases. Additionally, addressing the psychological and sexual health impact of vulvodynia is crucial for holistic care. Ongoing research on the underlying pathophysiology and emerging treatments provides new hope for improved management.

Conservative Therapies

Conservative treatment is typically the first line of intervention, focusing on pain reduction, symptom alleviation, and patient education. Behavioral therapies, including pelvic floor physical therapy, are often recommended. Pelvic floor muscle hypertonicity is frequently associated with vulvodynia and contributes to pain and sexual dysfunction. Physical therapy aimed at reducing pelvic floor tension through biofeedback and manual manipulation has been shown to reduce pain and improve sexual function in affected women effectively.

Topical treatments such as lidocaine and corticosteroids are commonly used to relieve pain. Lidocaine provides short-term analgesia, while corticosteroids target localized inflammation. However, the long-term efficacy of these treatments is limited, and they are typically recommended as adjuncts to other therapies.

Pharmacological Approaches

Pharmacotherapy, particularly when conservative measures alone prove insufficient, is another critical component of vulvodynia treatment. Antidepressants and anticonvulsants, such as amitriptyline and gabapentin, have been used due to their central and peripheral pain modulation properties. Both classes of drugs are commonly used for chronic pain syndromes and have shown moderate success in alleviating neuropathic pain associated with vulvodynia.

However, pharmacotherapy has limitations, including side effects such as drowsiness, weight gain, and cognitive impairments. Sleep disturbances often lead to treatment discontinuation. Additionally, pharmacological treatments do not address the underlying causes of vulvodynia and are more suitable for symptomatic relief than curative outcomes.

Surgical Interventions

Surgical intervention, primarily vestibulectomy or vestibuloplasty, is considered when conservative and pharmacological treatments fail to provide adequate relief. Vestibulectomy, involving the removal of affected vestibular tissue, has shown high success rates, with studies reporting long-term pain relief in up to 80% of patients. However, surgery carries risks, including scarring and altered sensation, and should be reserved for cases where less invasive options have been exhausted.

Vestibuloplasty is a simplified technique compared to vestibulectomy. It involves excising the distal circumference of the vulvar vestibule and removing underlying submucosal minor vestibular glands. Studies on this technique have shown mixed results.

Psychological Interventions

Considering the profound psychological burden of vulvodynia, including its impact on sexual health and quality of life, psychological interventions play a crucial role in comprehensive management. Cognitive-behavioral therapy (CBT) has been widely studied in chronic pain conditions and is beneficial for vulvodynia,

addressing maladaptive thought patterns, anxiety, and depression that may exacerbate pain perception. Additionally, sexual counseling, both individual and couples therapy, can improve sexual function and relationship satisfaction for women suffering from vulvodynia.

New Treatment Approaches

Hormonal Therapies: Hormonal imbalances, particularly estrogen and testosterone, are believed to contribute to the pathophysiology of vulvodynia. Consequently, hormonal therapies focusing on hormonal modulation have been developed. Low-dose vaginal estrogen and testosterone creams have proven effective in restoring vestibular tissue integrity and reducing pain by enhancing mucosal resilience.

Research is ongoing to explore new formulations and optimized application methods to improve therapeutic outcomes and patient compliance with localized hormonal therapies with minimal systemic side effects.

Management of Neuropathic Pain

Recent studies on the neuropathic component of vulvodynia have led to investigations into treatments commonly used in other neuropathic pain syndromes. Gabapentinoids, such as gabapentin and pregabalin, have garnered attention for their capacity to regulate abnormal nerve signaling. Clinical trials indicate that patients with vulvodynia treated with gabapentinoids experience promising reductions in pain sensitivity, particularly when combined with physical therapy. Similarly, the use of tricyclic antidepressants and selective serotonin-norepinephrine reuptake inhibitors has shown potential benefits due to their ability to modulate central pain processing pathways [62, 63].

Immune Modulation and Anti-Inflammatory Approaches

Given evidence suggesting an inflammatory etiology in some instances of vulvodynia, therapies aimed at reducing inflammation are being explored. Topical corticosteroids remain a cornerstone in reducing localized inflammation, though their long-term use is limited due to potential adverse effects on tissue integrity. Therefore, new approaches are being investigated, including those targeting specific inflammatory pathways. Although experimental, agents inhibiting tumor necrosis factor-alpha or interleukin-1 are exciting. The use of anti-inflammatory agents, such as low-dose naltrexone, has emerged as a potential treatment option due to its dual role in modulating pain and inflammation [24, 64, 65].

Botulinum Toxin Injections

Botulinum toxin is a promising therapeutic approach for treating vulvodynia. Targeting hyperactive muscles in the pelvic floor has proven effective in alleviating vestibular pain and reducing muscle tension. Several clinical studies report significant pain reduction and improvements in sexual function following botulinum toxin treatment, especially in patients with concurrent pelvic floor dysfunction. The potential for long-term relief through periodic injections offers an appealing option for patients unresponsive to traditional interventions [6, 66, 67].

Platelet-Rich Plasma (PRP) Therapy

PRP therapy, which involves injecting concentrated autologous platelets into affected tissues, has attracted interest for its regenerative properties. PRP releases growth factors that support tissue repair, reduce inflammation, and stimulate collagen production, making it an attractive option for treating vulvodynia. Preliminary studies on PRP injections into the vulvar vestibule report pain reduction and improvements in tissue health, though larger, well-controlled studies are necessary to fully establish its efficacy and safety profile in this population [26, 68, 69].

Low-Level Laser Therapy (LLLT)

Also known as photobiomodulation, LLLT is a noninvasive therapy that uses specific light wavelengths to support tissue healing and reduce inflammation. Traditionally used in musculoskeletal pain syndromes, its application in vulvodynia has shown promise. LLLT is believed to enhance mitochondrial function, improve cellular repair, and reduce neuropathic pain. Preliminary data suggest that LLLT may be especially effective when combined with other treatments, such as physical or hormonal therapy [49, 51, 70].

CBT and Psychosocial Interventions

Integrating psychosocial interventions, such as Cognitive Behavioral Therapy (CBT), into the treatment of vulvodynia is increasingly recognized as crucial for managing psychological issues associated with chronic pain syndromes. Emerging research highlights that addressing the psychological components of vulvodynia, such as anxiety, fear of pain, and sexual dysfunction, can enhance the overall effectiveness of other treatments. Multidisciplinary approaches that combine CBT with physical and pharmacological therapies may yield superior outcomes by addressing the condition's physical and emotional dimensions [71,72].

CONCLUSİON

Neuroproliferation, characterized by increased density of C-fiber nociceptors in the vestibular region, has emerged as a significant factor in the pain experienced by vulvodynia patients. This neurogenic component aligns with central sensitization, where the nervous system overreacts even to minimal stimuli. Moreover, recent research on hormonal influences suggests that changes in estrogen and testosterone levels may contribute to pain sensitivity by thinning the vestibular epithelium.

The heterogeneity of vulvodynia and the absence of a standardized diagnostic approach pose substantial challenges in clinical practice and research. The condition remains underdiagnosed, with many patients enduring prolonged pain before receiving an accurate diagnosis and effective treatment. Future research should focus on elucidating the underlying pathophysiology of vulvodynia, emphasizing the identification of biomarkers that could facilitate early diagnosis and targeted therapies. Advances in understanding central sensitization, neuroinflammation, and genetic predispositions may pave the way for more personalized and effective treatments.

Traditionally, vulvodynia has been diagnosed by exclusion, often requiring comprehensive differential workups to rule out infectious, dermatological, or malignant causes of vulvar pain. However, advances in diagnostic tools now offer more targeted approaches. Quantitative sensory testing allows clinicians to objectively assess pain thresholds and sensory abnormalities in the vulvar vestibule, aiding in differentiating vulvodynia from other vulvodynia subtypes. Additionally, advancements in imaging techniques, such as high-resolution magnetic resonance imaging, have begun to reveal structural abnormalities in the vestibular tissue underlying chronic pain in vulvodynia.

Another exciting development is the role of biomarkers in the diagnosis of vulvodynia. Research on molecular markers, such as nerve growth factors and specific proinflammatory cytokines, holds promise for more precise diagnostic criteria, potentially enabling earlier diagnosis and treatment.

Vulvodynia significantly impacts women's physical, emotional, and sexual health. Although progress has been made in understanding its underlying mechanisms, considerable gaps remain in its effective management. A multidisciplinary approach that includes medical, physical, and psychological therapies offers the best patient outcomes. However, research is needed to develop more effective, personalized treatments and improve the overall quality of care for women affected by this condition.

The management of vulvodynia remains a complex challenge due to its multifactorial nature. Nevertheless, recent advances in hormonal therapy, neuropathic pain modulation, anti-inflammatory treatments, and regenerative medicine offer promising new avenues for alleviating pain and enhancing quality of life. The ongoing exploration of therapies, such as botulinum toxin, PRP, low-level laser therapy, and psychosocial interventions, highlights the need for personalized, multimodal treatment strategies. Microsurgical approaches that target hyper innervated areas of the vestibule while preserving surrounding structures provide long-term relief in patients unresponsive to conservative treatments.

As new perspectives on its pathophysiology, diagnosis, and treatment emerge, the management of vulvodynia is evolving. Transitioning from a symptomatic approach to addressing underlying biological and psychosocial mechanisms offers hope for more effective, personalized care. With ongoing research on pharmacological therapies, minimally invasive procedures, and holistic interventions, vulvodynia management is becoming increasingly influential. For many women, the prospect of pain relief and improved quality of life is within reach. Continued collaboration among clinicians, researchers, and patients is essential to further developing these new horizons and optimizing therapeutic outcomes.

Future research should focus on large-scale clinical trials and the long-term safety of these emerging therapies, aiming to develop more effective and durable treatment paradigms for vulvodynia.

Funding: None

Conflicts of Interest: There are no conflicts of interest.

REFERENCES

1. Vieira-Baptista P, Lima-Silva J, Pérez-López FR, Preti M, Bornstein J. Vulvodynia: A disease commonly hidden in plain sight. Vol. 20, Case reports in women's health. Netherlands; 2018. p. e00079.
2. Henzell H, Berzins K, Langford JP. Provoked vestibulodynia: current perspectives. Int J Womens Health. 2017;9:631–42.
3. Sadownik LA. Etiology, diagnosis, and clinical management of vulvodynia. Int J Womens Health. 2014;6:437–49.
4. Brown C, Bachmann G, Foster D, Rawlinson L, Wan J, Ling F. Milnacipran in provoked vestibulodynia: efficacy and predictors of treatment success. J Low Genit Tract Dis. 2015 Apr;19(2):140–4.
5. Aksoy Ö, Sahin N. Vulvodini: Tanı, Tedavi ve Bakım. In 2020. p. 251–66.
6. Schlaeger JM, Glayzer JE, Villegas-Downs M, Li H, Glayzer EJ, He Y. Evaluation and Treatment of Vulvodynia: State of the Science. J Midwifery Womens Health. 2023 Jan;68(1):9–34.
7. Merlino L, Titi L, Pugliese F, D'Ovidio G, Senatori R, Rocca C Della. Vulvodynia: Pain Management Strategies. Pharmaceuticals (Basel). 2022 Dec;15(12).
8. Kliethermes CJ, Shah M, Hoffstetter S, Gavard JA, Steele A. Effect of Vestibulectomy for Intractable Vulvodynia. J Minim Invasive Gynecol. 2016;23(7):1152–7.
9. Stephens JR, Peters KM. A novel approach to

vulvodynia using targeted neuromodulation. Can J Urol. 2022 Feb;29(1):11032–5.
10. Barry CM, Matusica D, Haberberger RV. Emerging evidence of macrophage contribution to hyperinnervation and nociceptor sensitization in vulvodynia. Front Mol Neurosci. 2019;12:186.
11. Park SY, Lee ES, Lee SR, Kim SH, Chae HD. Vaginal microbiome is associated with vulvodynia, vulvar pain syndrome: a case-control study. Sex Med. 2021;9(2):100314.
12. Barnabei VM. Vulvodynia. Clin Obstet Gynecol. 2020;63(4):752–69.
13. Rozani S, Evangelou K, Tsagkaris C. Vulvodynia associated with vulvovaginal microbiome: Neglected due to the COVID-19 pandemic? Ethics, Med Public Heal. 2022;20:100746.
14. Bedford L, Parker SE, Davis E, Salzman E, Hillier SL, Foxman B. Characteristics of the vaginal microbiome in women with and without clinically confirmed vulvodynia. Am J Obstet Gynecol. 2020;223(3):406-e1.
15. Tiranini L, Cantamessi M, Serra E, Mariacci G, Tassorelli C, Nappi RE. Vulvodynia: when a training program to increase muscle mass in the lower limbs does some good! AboutOpen. 2023;10(1):119–23.
16. De Leo V, Governini L, Ponchia R, Recalcati D, Murina F. Effectiveness of Combination of Tibolone and Lactobacilli Plus Lactoferrin in Postmenopausal Women with Vulvar Vestibular Pain: A Preliminary Report. Nutrients. 2024;16(14).
17. Bornstein J, Palzur E. Neuroproliferative processes in vulvodynia. Female Sex Pain Disord Eval Manag. 2020;43–51.
18. Woelber L, Prieske K, Mendling W, Schmalfeldt B, Tietz HJ, Jaeger A. Vulvar pruritus—causes, diagnosis and therapeutic approach. Dtsch Arztebl Int. 2020;117(8):126.
19. Pope R, Austin B, Ghosalkar E. An Overview of Generalized and Localized Vulvodynia and Its Relationship to Female Sexual Dysfunction. Curr Sex Heal Reports. 2024;16(1):12–8.
20. Soogoor A, Narampanawe B. 10 Facts overlooking co-morbitities associated with vulvodynia. J Miss State Med Assoc. 2024;65(5/6).
21. Nimbi FM, Renzi A, Limoncin E, Bongiovanni SF, Sarzi-Puttini P, Galli F. Central sensitivity in fibromyalgia: testing a model to explain the role of psychological factors on functioning and quality of life. Clin Exp Rheumatol. 2024;42(6):1187–97.
22. Sutton KS, Yessick LR, Wild CJ, Chamberlain SM, Pukall CF. Exploring the neural correlates of touch and pain in women with provoked vestibulodynia. Pain. 2020;161(5):926–37.
23. Queiroz JF, Aquino ACQ, Sarmento ACA, Siqueira BB, Medeiros HD, Falsetta ML. Psychosocial Factors Associated With Vulvodynia. J Low Genit Tract Dis. 2024;10–1097.
24. Bergeron S, Reed BD, Wesselmann U, Bohm-Starke N. Vulvodynia. Nat Rev Dis Prim. 2020;6(1):36.
25. Guidozzi F, Guidozzi D. Vulvodynia–an evolving disease. Climacteric. 2022;25(2):141–6.
26. Vasileva P, Strashilov S, Yordanov A. Aetiology, diagnosis, and clinical management of vulvodynia. Menopause Rev Menopauzalny. 2020;19(1):44–8.
27. Baszak-Radomanska E, Wanczyk-Baszak J, Paszkowski T. Pilot study of testing a clinical tool for pelvic physical examination in patients with vulvodynia. Ginekol Pol. 2021;92(6):410–6.
28. Arora V, Mukhopadhyay S, Morris E. Painful sex (dyspareunia): a difficult symptom in gynecological practice. Obstet Gynaecol Reprod Med. 2020;30(9):269–75.
29. Vicente-Neira A, Prieto-Gómez V, Navarro-Brazález B, Lirio-Romero C, Bailón-Cerezo J, Torres-Lacomba M. Online information on painful sexual dysfunction in women: quality analysis of websites in SPANISH about dyspareunia, vaginismus and vulvodynia. Int J Environ Res Public Health. 2022;19(3):1506.
30. Barach E, Slavin MN, Earleywine M. Cannabis and vulvodynia symptoms: a preliminary report. Cannabis (Research Soc Marijuana). 2020;3(2):139.
31. Torres-Cueco R, Nohales-Alfonso F. Vulvodynia—it is time to accept a new understanding from a neurobiological perspective. Int J Environ Res Public Health. 2021;18(12):6639.
32. Jantos M. Pain mapping: A mechanisms-oriented protocol for the assessment of chronic pelvic pain and urogenital pain syndromes. Pelviperineology. 2020;39(1):3.
33. Rubal C, Pereira A, Sastre LC, Pérez-Cejuela BA, Gámiz SH, Chaves P. Managing vulvodynia with central sensitization: challenges and strategies. J Clin Med. 2023;12(11):3851.
34. Dunphy L, Wood F, Mubarak ES, Coughlin L. Levator Ani Syndrome Presenting with Vaginal Pain. BMJ Case Reports CP. 2023;16(5):e255190.
35. Baril S, Czuzoj-Shulman N, Abenhaim HA. Obstetric outcomes in women with vulvodynia or vaginismus. Arch Gynecol Obstet. 2023;308(2):471–7.
36. Chisari C, Monajemi MB, Scott W, Moss-Morris R, McCracken LM. Psychosocial factors associated with pain and sexual function in women with Vulvodynia: A systematic review. Eur J Pain. 2021;25(1):39–50.
37. Bohm-Starke N, Ramsay KW, Lytsy P, Nordgren B, Sjöberg I, Moberg K. Treatment of provoked vulvodynia: a systematic review. J Sex Med. 2022;19(5):789–808.
38. Penteado SRL, Bonduki CE, de Araújo TRE, Alves SV, de Luccas Batista NMT, Ambrogini CC. Individualized multidisciplinary therapy for vulvodynia. J Obstet Gynaecol Res. 2024;50(2):147–74.
39. Prendergast S, Akincilar E. Pelvic Floor Assessment of Vulvodynia. Female Sex Pain Disord Eval Manag. 2020;133–41.
40. Morin M, Dumoulin C, Bergeron S, Mayrand MH,

Khalifé S, Waddell G. Multimodal physical therapy versus topical lidocaine for provoked vestibulodynia: a multicenter, randomized trial. Am J Obstet Gynecol. 2021;224(2):189-e1.
41. Vogel JJ. Pain specialist management of sexual pain–IV. Pharmacological. Sex Med Rev. 2023;11(2):98–105.
42. Santangelo G, Ruggiero G, Murina F, Di Donato V, Perniola G, Palaia I. Vulvodynia: a practical guide in treatment strategies. Int J Gynecol Obstet. 2023;163(2):510–20.
43. Rachmania N, Rahmawati F. Comparison of the effectiveness and safety between gabapentin and amitriptyline in pain improvement in peripheral diabetic neuropathy patients: a review. Indones J Pharmacol Ther. 5(1).
44. Das D, Davidson ERW, Walters M, Farrell RM, Ferrando CA. Patient-centered outcomes after modified vestibulectomy. Obstet Gynecol. 2020;135(1):113–21.
45. Woodruff JD, Friedrich EGJ. The vestibule. Clin Obstet Gynecol. 1985 Mar;28(1):134–41.
46. Saçıntı KG, Razeghian H, Bornstein J. Surgical Treatment for Provoked Vulvodynia: A Systematic Review. J Low Genit Tract Dis. 2024 Aug;
47. Austin RE, Lista F, Vastis PG, Ahmad J. Posterior Vaginoplasty With Perineoplasty: A Canadian Experience With Vaginal Tightening Surgery. Aesthetic Surg J Open Forum [Internet]. 2019 Oct 7;1(4):ojz030. Available from: https://doi.org/10.1093/asjof/ojz030
48. David A, Bornstein J. Evaluation of Long-Term Surgical Success and Satisfaction of Patients After Vestibulectomy. J Low Genit Tract Dis. 2020 Oct;24(4):399–404.
49. Jackman VA, Bajzak K, Rains A, Swab M, Miller ME, Logan GS. Physical Modalities for the Treatment of Localized Provoked Vulvodynia: A Scoping Review of the Literature from 2010 to 2023. Int J Womens Health. 2024;16:769–81.
50. Donders G, Nderlita M, Vertessen VJ, Reumers J. Long Term Outcome of Surgical Treatment of Central Introital Dyspareunia. J Clin Med. 2022 Apr;11(8).
51. Starzec-Proserpio M, Bardin MG, Morin M. Not all lasers are the same: a scoping review evaluating laser therapy for vulvodynia. Sex Med Rev. 2023 Dec;12(1):14–25.
52. Reid R, Omoto KH, Precop SL, Berman NR, Rutledge LH, Dean SM. Flashlamp-excited dye laser therapy of idiopathic vulvodynia is safe and efficacious. Am J Obstet Gynecol. 1995 Jun;172(6):1684–701.
53. Stabile G, Scalia MS, Carlucci S, De Seta F. Ladylift(®) non-ablative laser technology for the treatment of menopausal vestibulodynia and genitourinary syndrome. Prz menopauzalny = Menopause Rev. 2022 Dec;21(4):253–8.
54. Brotto LA, Zdaniuk B, Rietchel L, Basson R, Bergeron S. Moderators of Improvement From Mindfulness-Based vs Traditional Cognitive Behavioral Therapy for the Treatment of Provoked Vestibulodynia. J Sex Med. 2020 Nov;17(11):2247–59.
55. Stenson AL. Vulvodynia: Diagnosis and Management. Obstet Gynecol Clin North Am. 2017 Sep;44(3):493–508.
56. Graziottin A, Brotto LA. Vulvar vestibulitis syndrome: a clinical approach. J Sex Marital Ther. 2004;30(3):125–39.
57. Hoffstetter S, Shah M. Vulvodynia. Clin Obstet Gynecol. 2015 Sep;58(3):536–45.
58. Dagostin Ferraz S, Rodrigues Candido AC, Rodrigues Uggioni ML, Colonetti T, Santina Dagostin V, Rosa MI. Assessment of anxiety, depression and somatization in women with vulvodynia: A systematic review and META-analysis. J Affect Disord. 2024 Jan;344:122–31.
59. Aday AW, Beckman JA. Medical management of asymptomatic carotid artery stenosis. Prog Cardiovasc Dis. 2017;59(6):585–90.
60. Brotto LA, Basson R, Carlson M, Zhu C. Impact of an integrated mindfulness and cognitive behavioural treatment for provoked vestibulodynia (IMPROVED): a qualitative study. Sex Relatsh Ther [Internet]. 2013 Feb 1;28(1–2):3–19. Available from: https://doi.org/10.1080/14681994.2012.686661
61. Loflin BJ, Westmoreland K, Williams NT. Vulvodynia: A Review of the Literature. J Pharm Technol jPT Off Publ Assoc Pharm Tech. 2019 Feb;35(1):11–24.
62. Ergisi M, Law A, Chaudhari N, Tsatsari S, Lawson K, Jenner C. Effectiveness of topical gabapentin in the treatment of vulvodynia: a narrative synthesis. Front pain Res (Lausanne, Switzerland). 2023;4:1159268.
63. Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008 Sep;112(3):579–85.
64. Falsetta ML, Foster DC, Woeller CF, Pollock SJ, Bonham AD, Piekna-Przybylska D. Toll-Like Receptor Signaling Contributes to Proinflammatory Mediator Production in Localized Provoked Vulvodynia. J Low Genit Tract Dis. 2018 Jan;22(1):52–7.
65. Foster DC, Hasday JD. Elevated tissue levels of interleukin-1β and tumor necrosis factor-α in vulvar vestibulitis. Obstet Gynecol [Internet]. 1997;89(2):291–6. Available from: https://www.sciencedirect.com/science/article/pii/S0029784496004474
66. Bhuiyan J, Habeshian KA, Booser AC, Gomez-Lobo V, Dowlut-McElroy T. Botulinum Toxin Injections as a Treatment of Refractory Vulvodynia in Adolescents: A Case Series. J Pediatr Adolesc Gynecol [Internet]. 2023;36(5):497–500. Available from: https://www.sciencedirect.com/science/article/pii/S

1083318823003406
67. Haraldson P, Mühlrad H, Heddini U, Nilsson K, Bohm-Starke N. Botulinum Toxin A as a Treatment for Provoked Vestibulodynia: A Randomized Controlled Trial. Obstet Gynecol. 2020 Sep;136(3):524–32.
68. Sattler S, Elsensohn AN, Mauskar MM, Kraus CN. Plasma cell vulvitis: A systematic review. Int J women's dermatology. 2021 Dec;7(5Part B):756–62.
69. Yun JSW, Veysey E. Plasma Cell Vulvitis: A Systematic Review of Interventions. J Low Genit Tract Dis. 2021 Jul;25(3):243–54.
70. Trutnovsky G, Bliem B, Greimel E, Tamussino K, Gold D. Microablative Erbium: YAG Laser Therapy for Vulvodynia - A Report on Efficacy, Safety, and Treatment Satisfaction. Vol. 9, Sexual medicine. England; 2021. p. 100432.
71. Moravek MB, Legocki LJ, Piper CK, Bernard K, Reed BD, Haefner HK. Impact of a single-session psychosocial counseling intervention for women with vulvodynia. Int J Gynaecol Obstet Off organ Int Fed Gynaecol Obstet. 2023 Jan;160(1):202–8.
72. Niedenfuehr J, Edwards M, King LM. A scoping review: the psychosocial barriers that exist for people with vulvodynia. J Sex Med. 2023 May;20(6):833–58.